INBRIJA Savings Programs

$0

CO-PAY

$0 CO-PAY

Commercially insured patients may be eligible to pay as little as $0 for their INBRIJA prescription. *Limitations and restrictions may Apply

Eligibility Restrictions Apply. For Questions, call 1-833-INBRIJA (1-833-462-7452)

Icon symbolizing support

Patient Assistance
Program (PAP)

No-cost medication to patients who meet specific program eligibility requirements

*Please note, restrictions and maximum benefits apply to Merz’s co-pay assistance program, including monthly and yearly maximums. For more information, call 1-833-462-7452. Merz may modify these maximums or discontinue the program at any time. In this case, any change to what commercial patients are required to pay will be communicated to patients by their specialty pharmacy. The actual amount patients have to pay will vary depending upon these maximums and their insurance benefit. See Full Terms and Conditions

Terms and Conditions

*Co-pay program eligibility, Terms and Conditions, and Program Limitations

Patients must:

  • Be 18 years of age or older
  • Be prescribed INBRIJA for an FDA-approved indication
  • Have commercial health insurance
  • Not covered by any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Veterans Affairs, Department of Defense, or TRICARE

This offer is valid only in the United States, excluding where its otherwise prohibited by law. Patients residing in the states of Massachusetts and Rhode Island are eligible for drug co-payment assistance only and are not eligible for other types of co-payment assistance, including but not limited to costs related to administration of the drug.

Patients who move from commercial to federally funded or state funded insurance will no longer be eligible for the program. Proof required for receiving payment for out-of-pocket drug costs includes a valid explanation of benefits (EOB) or specialty pharmacy invoice, which must be submitted with 180 days after each treatment. Patient/Guardian may not and agrees not to seek reimbursement for value received from the Program from any third-party payers, including flexible spending accounts or healthcare savings accounts. If at any time patient begins receiving coverage under any federal, state, or government-funded healthcare program, Patient is no longer eligible to participate in the Program and must call 1-833-INBRIJA (1-833-462-7452) between 8am – 8pm ET to stop participation. Restrictions may apply. This is not health insurance.

Patient/Guardian and pharmacist are responsible for notifying insurance carriers or any other third party who pays for or reimburses any part of the prescription filled using the Program as may be required by the insurance carrier’s terms and conditions and applicable law.

Once a patient is successfully enrolled into the Program, they will be automatically re-enrolled annually, for as long as your patient remains eligible. The patient is obligated to notify the program within thirty (30) days of any change in information provided in patient’s enrollment form. The patient may notify the Program at any time to terminate participation in the Program. The patient may submit a new enrollment form to make changes to any Program elections. This offer may not be combined with any other coupon, discount, prescription savings card, free trial, or other offer for INBRIJA.

This is a limited time offer, and Merz reserves the right to rescind, revoke, amend, or terminate this offer, or the program in its entirety, at any time without notice.

Patient Assistance Program

For information about the eligibility requirements of the Merz Patient Assistance Program, call 1-833-INBRIJA (1-833-462-7452).

INBRIJA® Indication

INBRIJA® (levodopa inhalation powder) is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.

Important Safety Information
CONTRAINDICATIONS
  • INBRIJA is contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to risk of hypertension.
WARNINGS AND PRECAUTIONS
  • Patients treated with levodopa have reported falling asleep during activities of daily living, including operation of motor vehicles, which sometimes resulted in accidents. Many patients reported somnolence but some reported no warning signs (sleep attack). Some of these events were reported more than a year after initiating treatment. Reassess patients for drowsiness/sleepiness including occurrence during specific activities. Advise patients of potential for drowsiness and ask about factors that may increase this risk.
    • Consider discontinuing INBRIJA in patients who report significant daytime sleepiness or falling asleep during activities that require active participation. If continuing INBRIJA, advise patients not to drive and to avoid activities that may result in harm. There is insufficient information that dose reduction will eliminate episodes of falling asleep during activities of daily living.
  • Neuroleptic malignant syndrome-like symptoms (e.g., elevated temperature, muscular rigidity, altered consciousness, autonomic instability) have been reported with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy.
  • Hallucinations and abnormal thinking and behavior may occur. Because of the risk of exacerbating psychosis, patients with a major psychotic disorder should ordinarily not be treated with INBRIJA and dopamine antagonists used to treat psychoses may exacerbate PD symptoms and decrease the effectiveness of INBRIJA.
  • Patients treated with INBRIJA can experience intense urges to gamble or spend money, increased sexual urges, binge eating, and/or other intense urges, and inability to control them. In some cases, these urges stopped with dose reduction or medication discontinuation.
  • INBRIJA may cause or exacerbate dyskinesias. If troublesome dyskinesias occur, consider stopping INBRIJA or adjusting other PD medications.
  • INBRIJA is not recommended in patients with asthma, COPD, or other chronic underlying lung disease because of the risk of bronchospasm.
  • Monitor patients with glaucoma for increased intraocular pressure.
  • Abnormalities in laboratory tests may include elevations of liver function tests (e.g., alkaline phosphatase, AST, ALT, lactic dehydrogenase, bilirubin), blood urea nitrogen, hemolytic anemia, and positive direct antibody test. Increased levels of catecholamines and their metabolites in plasma and urine may result in false-positive results suggesting pheochromocytoma.
ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and higher than placebo) were cough (15% vs 2%), upper respiratory tract infection (6% vs 3%), nausea (5% vs 3%), and sputum discolored (5% vs 0%).

DRUG INTERACTIONS

Use of selective MAO-B inhibitors with INBRIJA may be associated with orthostatic hypotension. Monitor patients taking these drugs concurrently. Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone, metoclopramide) and isoniazid may reduce levodopa efficacy; monitor patients for worsening PD symptoms. Iron salts or multivitamins with iron salts may reduce levodopa bioavailability.

USE IN PREGNANCY AND LACTATION

There are no adequate data on the developmental risk associated with INBRIJA in pregnant women or on the effects on breastfed infants. Animal data shows carbidopa/levodopa is developmentally toxic (including teratogenicity). Levodopa may interfere with lactation. Levodopa has been detected in human milk.

PEDIATRIC USE

Safety and effectiveness in pediatric patients have not been established.

GERIATRIC USE

Patients 65 years of age and older (n=56) experienced more of the following adverse reactions than patients <65 (n=58): cough (25% vs 5%), upper respiratory tract infection (11% vs 2%), nausea (7% vs 3%), vomiting (4% vs 2%), pain in extremities (4% vs 0%), and discolored nasal discharge (4% vs 0%).

Visit www.inbrija-hcp.com to obtain the Full Prescribing Information, Patient Information and Instructions for Use.

IMPORTANT SAFETY INFORMATION

INBRIJA is contraindicated in patients taking or who have recently taken (within 2 weeks) nonselective monoamine oxidase (MAO) inhibitors (e.g., phenelzine and tranylcypromine) due to risk of hypertension.

WARNINGS AND PRECAUTIONS

Patients treated with levodopa have reported falling asleep during activities of daily living, including operation of motor vehicles, which